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IDENTIFICATION OF MORE POTENT AND EFFICACIOUS ANALOGS 
OF THE NOVEL HOST-DERIVED IMMUNOSTIMULANT EP67 
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Supervisor: Joseph A. Vetro, Ph.D. 
EP67 is a decapeptide agonist of C5a Receptor 1 (C5aR1/CD88) based on 
the C-terminus of human C5a that selectively activates mononuclear phagocytes 
over neutrophils to stimulate protective innate and adaptive immune responses 
while potentially minimizing neutrophil-mediated toxicity. Pro7 and N-methyl-Leu8 
(nme-Leu8) induce structural changes within EP67 that increase potency and 
selective activation vs. neutrophils. Cis/trans isomerization at Pro7, however, likely 
limits the activity of EP67 and the low coupling efficiency between Pro7 and nme-
Leu8 increases scale-up costs for clinical use. Thus, the goals of this project were 
to (i.) develop a clinically relevant, high-throughput assay for screening 
immunostimulant activity in primary human mononuclear phagocytes (monocytes, 
unpolarized (M0)-monocyte-derived macrophages, monocyte-derived dendritic 
cells) and neutrophils and (ii.) determine whether replacing Pro7 with 
cyclohexylalanine and/or nme-Leu8 with leucine adversely affects EP67 potency 
and efficacy in human mononuclear phagocytes and selective activation vs. human 
neutrophils. We found that, depending on the mononuclear phagocyte and 
cytokine, EP67 analogs (i.) had similar or lower EC50 and similar, increased, or 
decreased EMAX for IL-6 and TNF-α secretion from mononuclear phagocytes 24 h 
after treatment and (ii.)  EP67 analogs does not affect selective activation of 
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mononuclear phagocytes vs. neutrophils. Thus, replacing Pro7 and/or nme-Leu8 
with amino acids that induce similar structural changes affects the activity of EP67 
depending on the mononuclear phagocyte and cytokine but is an amenable 
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1 GENERAL INTRODUCTION  
1.1 Chance and necessity: The first attempt of immunostimulants 
The concept of immunostimulants was initiated early last century when Dr. 
William Coley, a renowned surgeon at New York Memorial hospital, utilized killed 
streptococcus pyogenes and Serratia marcescens (Coley’s vaccine) to treat 
lymphomas, melanomas, and myelomas. His insight was that active defense 
against microbes reinforced the body's fight against cancer. This observation leads 
to the origin of the combination of streptococcus pyogenes and Serratia [1]. 
Initially, Coley and other researchers were using live bacteria; however, the fatal 
infection caused by these induced bacteria led to the use of inactivated organisms. 
After the success of using inactivated organisms, several other microbial 
substances were clinically approved to be used in the treatments of infections and 
cancers (Table 1.1) [2]. However, the use of immunostimulants to enhance the 
humoral immunity was recognized later, in 1925, when Gaston Ramon observed 
that giving diphtheria toxoid with the combination of starch, fish oils, and several 
plants extract can enhance the response of antibodies towards the toxoid in the 
horses. Following this, after a year, Glenny also observed the same effect with 
Alum, which was approved later as an adjuvant in a variety of vaccines [3-5]. 
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Immunostimulants are either natural or synthetic substances that are used 
to induce and stimulate nonspecific activation of the immune system, unless they 
are associated with antigens (e.g., adjuvants in vaccines). Immunostimulants can 
amplify different effectors of the immune response, including phagocytosis, 
complement system, protective secretory antibodies, α- and γ-interferon release, 
T- and B-lymphocytes, and synthesis of pulmonary surfactant [1,6]. They also 
support the release of endogenous immune mediators such as cytokines and 
chemokines that aids in the treatments of several chronic diseases such as 
infectious diseases, immunodeficiencies, or cancer. Immunostimulants vary based 
on their origin, mechanism of action, and application (preventive, therapeutic, or 
adjuvants) [1]. 
1.2 The impact of immunostimulants 
Through the last three decades, there have been intensive researches that 
are carried out on the development, preparation, experimental, and clinical 
characteristics of immunostimulants. From the therapeutic point of view, the ability 
of immunostimulants to stimulate the immune system has a great potential as 




One of the greatest achievements of modern medicine has been the 
development of antimicrobials for the treatment of infectious diseases [8]. Antibiotic 
resistance, however, has turned into a significant medical problem. For instance, 
staphylococcus aureus penicillin resistance has been reported since 1947, four 
years after the start of large-scale production, and since then, the amount and 
variety of pathogenic strains resistant to new classes of antibiotics have increased 
[9,10]. This has made various treatment schemes with antimicrobial drugs less 
effective. Therefore, the interest in the development of new alternatives for the 
treatment of bacterial infections has become a global emergency [11]. Combating 
pathogenic organisms by combined therapies involving appropriate immune 
response molecules and antimicrobial drugs represents an apparent and 
successful therapeutic paradigm for the treatment of acute and chronic infectious 
diseases [12]. Several studies have demonstrated the abilities of different 
immunostimulants to stimulate host defense mechanisms for the prophylaxis and 
treatment of diverse viral, bacterial, parasitic, and fungal diseases. The potential 
of these agents to stimulate the immune response can be used for treatment or as 
adjuvant therapy of various microbial infections [13]. 
In the case of vaccination, adjuvants are substances used to increase the 
cellular/humoral response to a used immunogen to prevent infectious diseases.  In 
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general, among the mechanisms that adjuvants use to boost the immune response 
are the "deposit" effect, antigen presentation, antigen distribution, immune 
modulation/activation, and induction of cytotoxic lymphocytes [14,15]. Adjuvants 
can significantly improve the protective immune response, and today their in-depth 
knowledge is the key to the development of better vaccines. The classic adjuvant 
at present is the aluminum salts (aluminum phosphate and aluminum hydroxide), 
which discovered in the first half of the twentieth century [16]. These adjuvants, in 
addition to being deposited in a particulate manner in the tissues and inducing 
phagocytosis of the antigen, activate macrophages, stimulate the T helper 2 
response (Th2) and are frequently used when the immunological effector sought 
is antibodies, since they stimulate the production of IgG 1 [16,17]. They do not 
significantly stimulate cellular immunity, since the adjuvant adsorbs to proteins, 
and the physicochemical conditions of antigen and adjuvant must be considered 
in this process. Recently, new aspects of the mechanism of action of aluminum 
hydroxide have been described, including the activation of the innate immune 
system and the production of IL-1, through the activation of the NPLR3 protein 
complex in monocytes and induction of immunogenic dendritic cells [18]. AS04 is 
another approved adjuvant that is made by a combination of aluminum salt and a 
Toll-like receptor 4 agonist (TLR4), monophosphoryl lipid A (MPL). MPL is 
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produced by detoxification and purification of lipopolysaccharides (LPS), 
originating a non-toxic molecule with immunostimulatory properties of TLR. The 
AS04 system causes a local transient response of cytokines that increases the 
activation of monocytes, dendritic cells, and antigen-specific T cells. This adjuvant 
system has been incorporated into some vaccines, such as Cervarix, approved for 
use against human papillomavirus and in the hepatitis B surface antigen vaccine 
(Fendrix), developed for patients with kidney disease and high risk of hepatitis B 
[19,20]. 
Also, natural, synthetic, or modified adjuvants are evaluated, which can be 
used to stimulate the immune response against specific pathogens. Such is the 
case of adjuvants MF59, an emulsion of squalene-tween 80 and sorbitan trioleate, 
which is a natural organic compound originally extracted from the shark's liver. 
MF59 is approved in Europe and is present in various vaccines, such as influenza. 
Another example is AS03, oil-water emulsion, and vitamin E and AS02 containing 
MPL and QS21 oil-water emulsion [21,22]. 
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1.3 A turning point: Better understanding of immunology and its impact on 
the development of immunostimulants 
For decades, the discovery and development of novel immunostimulants 
have been based on observations and experiments, without explicit immunological 
knowledge of the mechanism that causes the immunostimulatory effect. However, 
the discovery of the innate immune system's ability to recognize molecular 
pathogen-associated molecular patterns (PAMPs), via specialized receptors, 
pattern recognition receptors (PRRs), has had significant consequences for the 
development of new immunostimulants. PRRs are innate immunity receptors 
being involved in many immunological and immunopathological processes. 
Recently, several new families of PRRs have been identified including Toll-like 
receptors (TLRs), C-type lectin-like receptors (CLRs), nucleotide oligomerization 
domain (NOD) like receptors (NLRs), and Retinoic acid-inducible gene-1 (RIG-1) 
like receptors (RLRs) [23-25]. 
The innate immune system acts as a sentinel: the cells that are activated 
on contact with the PAMPs (especially the dendritic cells), which triggers their 
maturation, which enables them to efficiently present the antigen to the T 
lymphocytes, in the context of major histocompatibility complex (MHC system) 
[26]. The recognition of PAMPs by PRRs (especially TLRs) generates a cascade 
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of activation within the immune cells. This cascade results in the activation of a 
nuclear transcription factor (NFκB), which allows the transcription of inflammatory 
mediator genes such as proinflammatory cytokines (IL-1,IL-6, and TNFα), 
chemokines, adhesion molecules and cyclooxygenases-2; leading to attract more 
T cells to the point of inflammation and cause them to differentiate into polarized 
effectors. This discovery naturally led to the use of PAMPs as immunostimulants 
[27]. 
1.4 Classification of immunostimulants 
Most immunostimulants reviews during recent decades followed different 
criteria to classify the immunostimulants. In this section, immunostimulants are 
classified based on their origin. Also, the mechanism of actions of these 
substances will be highlighted according to the cell induction capacity and the type 
of response they initiate.  
1.4.1 Microbially-derived immunostimulants 
1.4.1.1 Bacterial lipopolysaccharides endotoxins  
The lipopolysaccharides of Gram-negative bacteria are prototype of 
PAMPs. LPS contains a fraction called lipid A, composed of fatty acids linked by 
steric bonding to N-acetylglucosamine molecules.  Another fraction is the R region, 
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which is composed of hexoses, and the third fraction is the so-called O antigen, 
which is specific for each bacterial species [28]. These molecules are essential to 
the bacterial wall structure and are well-known activators of the inflammatory 
response. The PRRs involved in the recognition of LPS has long remained 
unknown, however, Poltorak and colleagues have identified the role of TLR4 as 
LPS-sensing receptor. The recognition of LPS via TLR4 induce a signaling 
pathway involving the myeloid differentiation 88 (MyD88) cytoplasmic molecule 
that contains a Toll-Interleukin receptor domain (TIR domain) and a death domain 
(DD). After recruitment, the MyD88 molecule induces the recruitment and the 
activation of the Interleukin-1 receptor-associated kinase 1 and 4 (IRAK kinases 1 
and 4), responsible for the activation of the molecule TNF Receptor Associated 
Factor 6 (TRAF6). This then activates the NFκB, which is involved in the induction 
of many genes, mainly pro-inflammatory cytokines. Moreover, activation of TLR4 
induce the activation of the TRIF molecule, a step required to produce type I 
interferon: TRIF activates the IRF3 transcription factor, and it is binding on the 
promoter of the IFNβ gene [29-31]. Several synthetic analogs of the constituents 
of biologically active bacterial cell walls, such as lipid A, part of the LPS of gram-
negative bacteria, and synthetic muramyl dipeptide derived from bacterial 
peptidoglycan have prepared [32,33].  
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1.4.1.2 Unmethylated Cytosine-Phosphate-Guanosine Motifs (CpG Motifs) 
The synthetic oligonucleotides (ODN) of the CpG are single-stranded DNA 
sequences containing CG or CpG motifs. There are several classes of CpG-like 
ODNs (A, B, C, and P) that differ in their structure and immunostimulatory effect 
[34]. The CpG type ODNs are potent immunostimulants capable of activating most 
innate immunity cells such as natural killer cells (NK cells), T lymphocytes, B cells, 
monocytes, macrophages and DCs by detecting the intracellular presence of the 
cell DNA of phagocytotic pathogens [34,35]. The CpG type ODNs are 
predominantly recognized via the TLR9 receptor, which is located in endosomes 
and is primarily expressed by plasmacytoid Dendritic Cell (pDC) and B cell 
lymphocytes in humans, and in addition by the myeloid lineage (macrophages, 
monocytes, myeloid dendritic cells) in mice [36]. Human TLR9 would also be 
expressed in monocytes and macrophages but at a lower level [37]. 
Intracellular activation after TLR9 binding leads to the activation of mitogen 
activated protein kinases (MAP kinases) and NFκB pathways [36]. The attachment 
of CpG-like ODD to TLR9 in B cells triggers the secretion of cytokines such as IL-
6 and IL-10, cell proliferation, and expression of MHC class II molecules [38]. Type 
A ODDs strongly activate NK cells and pDCs and cause strong interferon- γ (IFN-
γ) secretion by pDCs while type B ODNs strongly activate B-cells and pDCs. The 
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C-type ODNs combine the properties of the two previous types. P-type ODNs 
stimulate B-cells, activate pDCs and induce strong IFN-γ secretion by pDCs such 
as type-A ODNs [36]. 
CpG-type ODNs are used either alone to promote an immune response, or 
in combination with other treatments such as monoclonal antibodies, 
chemotherapy, radiotherapy to increase its effectiveness, or as adjuvants in a 
vaccine. Several studies on solid tumor models have shown the effect on tumor 
development of the CpG-type ODN used alone [39-41]. For instance, a murine 
model of neuroblastoma has shown that a daily injected of CpG-type ODN near 
the tumor led to tumor regression in half of the animals, and the appearance of a 
prolonged protective immune response. Moreover, the combination of therapeutic 
monoclonal antibodies with CpG-type ODN increases the cytotoxicity relayed by 
antibodies by stimulating macrophages and NK cells. The combination of 
Trastuzumab (anti-Her2neu antibody) with CpG-type ODN, for instance, has 
shown to inhibit murine tumor growth in 96% of the human cell lines (MCF-7 and 
BT474 xenografts) [42]. In an orthotopic model of a pancreatic tumor, the 
combination of Gemcitabine and ODN CpG type allows to delay tumor 
development and increase the survival rate and reduces the spread of the tumor 
in the peritoneal cavity than the chemotherapeutic treatment alone [43]. Many 
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other mouse model studies have also shown improved efficacy of therapeutic 
treatments when combined with CpG-like ODNs. As a result, several clinical trials 
using CpG-type ODDs alone or in combination are underway [44]. 
1.4.1.3 Bacillus Calmette and Guerin (BCG) and active components of the 
mycobacterial cell wall 
BCG is a highly complex immunogen that induces a cellular-type immune 
response [1,45]. In 1921 Calmette and Guerin, after 13 years and 230 cultivation 
passes of a strain of Mycobacterium bovis, obtained a non-pathogenic but 
immunogenic bacillus, whose use managed, with varying efficacy, to reduce the 
incidence of tuberculosis and tuberculous meningitis for its systemic protective 
immunostimulatory effect [1]. 
Although BCG has been used successfully for many years, details of its 
antineoplastic mechanism of action remain unknown. It is thought that a wide 
variety of immunocompetent cells, as well as uroepithelial cells and even the same 
bladder neoplastic cells, participate in the immune mechanism that occurs during 
intravesical therapy with BCG [45]. The anti-tumor effects of BCG appear to be 
related to immunological mechanisms, which are reflected by a transient increase 
in several cytokines and the presence of immunocompetent leukocytes activated 
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in the urine within 24 hours after instillation [46]. Some studies have revealed that 
CD4 + T cells and monocytes act as accessory cells in cell-mediated cytotoxicity 
induced by BCG [47]. Certainly, another large number of molecules and cells must 
participate in BCG-induced immune stimulation, such as the family of adhesion 
molecules, heat shock proteins, toll-like receptors, nitric oxide, dendritic cells and 
their subpopulations, the regulatory T cells and the recently described Th17 cells 
[48,49].  
1.4.1.4 β-glucans 
β-glucans are polysaccharides formed from units of glucose linked together 
in β-1,4 and β-1,6. They differ in their structures (length and ramifications). These 
are compounds of the walls of fungi, yeasts, bacteria, algae, and plants, known in 
traditional medicine as immunostimulants [50,51]. Indeed, fungi and algae have 
branches rather than 1 to 6, while bacteria and plants have more side chains in 1 
to 4. The existing multiple β-glucans exhibit differences in immunostimulatory 
properties, and their polydispersity explains the complexity of purifying and 
studying them [52]. 
Macrophages can internalize β-glucans, fragment them in endosomes, and 
the released fragments of soluble β-glucans are then recognized by different 
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immune cells with specific receptors [53]. The primary receptors of known β-
glucans are lectins such as dectin-1 expressed on the surface of macrophages, 
neutrophils, and dendritic cells and integrins such as the type 3 complement 
receptor (CR3) expressed on the surface of NK cells and neutrophils [54,55]. They 
can also be recognized by the scavenger receptor and by the LactosylCeramide 
receptor (LacCer) expressed on the surface of neutrophils. CR3 recognizes 
opsonized or non-complemented β-glucans and directly induces phagocytosis. 
Thus, by binding to this receptor, β-glucans would cause a CR3 conformational 
change allowing better exposure of the iC3b binding domain, thus facilitating the 
interaction between integrin and its ligands and thus the activation of NK cells and 
neutrophils involved in the elimination of cancer cells [56]. 
Several clinical trials have demonstrated that the combination of 
chemotherapy with β-glucans promotes the activation of CR3 on NK cells and 
increases the effectiveness of treatment [57]. A study has shown that a group of 
mice inoculated with tumor cells had a significant slowing down of the increase in 
tumor size with a treatment combining the antitumor monoclonal antibody and the 
β-glucans compared to treatment with the antibody alone or β-glucans alone. Also, 
100 days after tumor implantation, a significant percentage of survival of mice 
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treated with monoclonal antibodies and β-glucans was observed, compared to 
other types of treatments [58].  
1.4.2 Synthetic-derived immunostimulants 
1.4.2.1 Levamisole (Ergamisol):  
Levamisole was initially developed as an anthelmintic and widely used for 
the treatment of gastrointestinal and tissue helminths [59]. Various studies have 
been carried out to demonstrate the immunostimulatory activity of levamisole, 
some of them with conflicting results. This drug, when administered in combination 
with the canine parvovirus vaccine, boosted antibody production, increased 
phagocytic activity and stimulated lymphocyte proliferation activity and similarly 
potentiated the protective antibody response to hepatitis B vaccination in patients 
with hemodialysis [60]. The effect of levamisole on cellular immunity is mainly on 
anaerobic T lymphocytes, macrophages and polymorphonuclear leukocytes [61]. 
In 2000, the US FDA was withdrawn Levamisole from the market due to its ability 
to cause serious adverse effects, including agranulocytosis [62]. Interestingly, 
levamisole has been found as an adulterant in cocaine and can lead to a variety 




Isoprinosine is an antiviral, antitumor, and immunostimulatory agent with 
superior properties to levamisole. Isoprinosine works as a thymomimetic hormone, 
promoting the production of a factor that activates the functions of the various 
cytokines and increases the production of IL-1, IL-2, and interferon. It facilitates 
the differentiation of T lymphocytes and the increase of its receptors [64]. It is also 
able to increase the phagocytosis function of macrophages and cellular and 
humoral responses [65]. It is used in the treatment of viral infections, such as 
herpes simplex and encephalitis of viral origin [66]. 
1.4.3 Thymus-derived immunostimulants 
Thymic hormones are soluble substances obtained from the thymus 
(Thymopoietin, Thymostimulin, Thymosin, Thymulin), which were attributed with a 
favorable effect of maturation of T lymphocytes in this organ. This hormone is 
considered to induce maturation of pre-T cells; therefore, the purified hormone has 
therapeutic application potentials in various states of T-cell deficiency [67]. A 
recombinant peptide derived from this hormone; thymosin alpha-1 induces 
increases in the production of IL-2 and the expression of IL-2 receptors in T 
lymphocytes. This peptide is being studied in clinical experiments for the treatment 
of cancer and chronic active hepatitis [68]. In general, thymic hormones may have 
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utility in primary and secondary immunodeficiencies causing differentiation of non-
functional precursors in immunocompetent T cells. Among the side effects 
observed with these factors are allergic reactions, especially with poorly purified 
preparations [69]. 
1.4.4 Host-derived immunostimulants 
1.4.4.1 Exogenous Cytokines 
Cytokines are specific non-antigen soluble proteins, mostly produced by 
leukocytes that regulate immune system cells and inflammatory processes [2].  
These regulatory molecules are involved in the protective response against 
neoplasms and infections [2]. Although some cytokines are produced by 
mononuclear cells, either constitutively or in response to activation signals, their 
induction has been shown to be diminished in patients with chronic infectious 
diseases so they could benefit from the exogenous administration of these 
molecules [70]. When cytokines are used to induce immune response, the local 
advantages are 1) generate high concentrations of cytokines locally, similar to the 
body's response against foreign antigens; 2) take advantage of the paracrine 
effects of cytokines in a sustained way that activates the immune system [70,71].  
Some cytokines stimulate the production of others, therefore that they interact, 
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either synergistically or antagonistically and thus their local and systemic effects 
are intimately involved in the control of host infections [70]. 
Advances in the understanding of the role of cytokines in inflammatory and 
immune disorders have led to the development of cytokine-based therapies. These 
molecules, their receptors and their signaling pathways, are promising candidates 
for therapeutic participation [71].  The precise understanding of the critical balance 
between pro-inflammatory and regulatory cytokines in microbial infections is 
essential to be able to use and regulate with certainty and safety the beneficial 
effects that are sought through cytokine therapy, thus exploiting its great potential 
to increase resistance against various pathogens [72]. T helper cells 1 (Th1) are 
crucial for orchestrating cytokine responses and of utmost importance for the 
elimination of infectious diseases. These cells produce IFN-γ, TNF-β, and IL-2 
required for the effective development of the cell-mediated immune response 
against intracellular microorganisms [73]. On the other hand, Th2 produce IL-4 and 
IL-5 that enhance humoral immunity to T cell-dependent antigens and immunity 
against helminth infections [73]. Therefore, patients in whom cytokine production 
is altered or in those who carry out chemotherapy treatments, which causes an 




Interferons are cytokines initially described in 1957 with an action that 
interfered with viral replication. They were initially classified according to the cell 
that secreted them into IFN-α or leukocyte (produced by mononuclear 
phagocytes), IFN-β, or fibroblastic (produced by fibroblast) and IFN-γ (produced 
by lymphocytes and NK cells). They are currently classified according to their 
receptors and the homology of their sequences. Interferons such as IFN-α and 
INF-β are classified as type I, and IFN-γ is the only one classified as type II [75]. 
The mechanism of action of IFN-α and INF-β is related to inhibition of 
replication and viral spread. It also activates and regulates the expression of the 
MHC I. IFN-γ stimulates and activates macrophages, neutrophils and NK cells in 
their phagocytic and cytotoxic functions, in addition to inciting the expression of 
molecules of the MHC I [75]. IFN-α (INTRON A) is indicated in the treatment of 
hepatitis B and C and as an adjuvant in myeloma [76]. On the other hand, IFN-γ 
(ACTIMMUNE) is recommended as adjuvant therapy in chronic granulomatous 
disease, a primary immunodeficiency defect in phagocytic function in neutrophils 
and malignant osteopetrosis [77]. 
Interleukin 2 is a potent activator of T lymphocytes, activates NK cells, 
macrophages, B lymphocytes and stimulates the release of several cytokines. Its 
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antitumor effect is mediated by promoting the activation of NK cells, lymphokine-
activated killer cells (LAK) and other cytotoxic cells, as well as the induction of IFN-
γ, TNF-α [78]. The use of IL-2 in therapy cancer gene has been widely used in 
various preclinical tumor models, including hepatocellular carcinoma, head, neck 
carcinoma, sarcomas, plasmacytoma, breast carcinoma, lymphomas, and in 
cervical cancer [79]. Particularly, the effect IL-2 adjuvant in cervical cancer has 
been tested in tumor models associated with human papillomavirus (HPV). It has 
been shown that treatment with the recombinant protein of IL-2 gene, administered 
intratumorally, significantly reduces the progression of HPV-associated tumors 
and inhibits the formation of recurrent tumors after being removed by surgery [80]. 
Cytokines have also been described as a double-edged sword, as they 
have been attributed to both beneficial and harmful effects. Capillary filtration 
syndrome is the main dose-dependent toxicity in cytokine therapy, specifically IL-
2. This syndrome is characterized by an increase in vascular permeability 
accompanied by extravasation of fluids and proteins that produces interstitial 
edema and organ failure. The pathogenesis of endothelial cell damage is 
complicated. It may involve the activation or damage of endothelial cells and 
leukocytes, the release of cytokines and mediators of inflammation, the alteration 
of cell-cell, matrix-cell adhesion, and function of the cytoskeleton [81,82]. The 
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efficacy of exogenous cytokines capable of enhancing normal host defense 
mechanisms may be reduced to immunocompromised patients lacking effector 
cells or containing disease-related factors that prevent lymphocyte activation. 
1.4.4.2 Heat shock proteins  
Heat shock proteins (Hsps) are proteins that are synthesized by the body in 
response to stress (temperature, exposure to heavy metals, infections, etc.). They 
have been grouped into families according to their molecular mass: Hsps 60, Hsps 
70, Hsps 90, Hsps 110. These proteins are part of the family of molecular 
chaperones, and they associate with peptides or proteins that are not correctly 
folded. Hsps are used to prevent the accumulation of incorrectly folded proteins. 
Indeed, heat stress can result in denaturing proteins [83]. 
The participation of Hsps in infections and immune reactions occurs at 
many levels. It is therefore not surprising to observe a growing interest in these 
proteins in the search for new vaccines. For instance, mice vaccinated with a cell 
line that expresses a mycobacterial Hsps 60 show remarkable protection against 
lethal doses of Mycobacterium tuberculosis [84]. Moreover, Hsps 70 and Hsps 25 
are expressed during the cycle of the acquired immunodeficiency virus (HIV-1) and 
associate with specific viral proteins. They then serve as a target for NK cells and 
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the antibody-dependent cytotoxic cellular response; they have therefore been 
proposed as a "vehicle" (or vector or excipient) for the antigen in the development 
of HIV-1 vaccines [85]. In the case of autoimmune diseases, it has also been 
observed that the administration of epitopes of Hsps 60 and Hsps 70 could 
modulate the autoimmune reaction via immunization involving suppressor T cells 
or via induction of lymphocyte clone anergy. Self-reactive T involved; this can be 
used as a preventive as well as a curative treatment [86]. 
Hsps also play a role in the body's defense against cancer and currently 
represent a preferred target for the development of cancer therapeutics. Research 
on the understanding of the immune response to cancer has demonstrated the 
involvement of some members of the Hsps family in inducing specific protection 
against cancer. The importance of molecular chaperones in the recognition by the 
immune system of tumor cells and the subsequent regression of tumors has been 
demonstrated in animal models [87,88]. Some Hsps (Hsps 90 Grp94 and Hsps 70) 
have been detected on the surface of tumor cells where they could activate the 
immune response. These observations first led to the conclusion that they 
represented antigens recognized by the immune system. It was thus demonstrated 
that tumor-infiltrating T cells were able to recognize cells expressing Hsps 70, thus 
suggesting that these specific T cells could support the local antitumor cellular 
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response [89]. Another group of studies suggests that Hsps 70 and Hsps 90 
participate in the antitumor immune response as carriers of tumor antigen peptides 
and not as antigens themselves [90].  
1.4.4.3 Complement-derived immunostimulants (CDI) 
The complement system was discovered in the late 1890s. It is described 
as a serum thermolabile component, which has antimicrobial properties, capable 
of complementing the action of antibodies. Since then, knowledge has evolved, 
and it is now established that this system is an integral part of the innate immune 
system. This system refers to a set of serum proteins that play a crucial role in 
innate immunity: allowing the host to defend against pathogens, participating in the 
elimination of their cells under the condition of apoptosis. On the surface of 
apoptotic cells or the pathogen, the complement system can be cascaded in three 
ways: the classical pathway, the lectin pathway, or the alternative pathway. These 
three pathways converge to result in the activation of the complement system, 
which results in the release of several biologically active peptide fragments C3a 
C4a, and C5a called anaphylatoxins that have diverse biological functions. These 
fragments are biologically active cleavage products of the more abundant 
complement proteins C3, C4 and C5, respectively. Apart from their direct action, 
each of these pathways can induce inflammatory responses and modulate innate 
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and adaptive immune responses leading to the elimination of pathogens, immune 
complexes, and apoptotic cells [91,92]. 
One of the biological consequences of the activation of the complement 
system is the release of C3a, C4a, and C5a cationic peptides. Initially, C5 
convertase from the classical (C4b2a3b), lectin (C4b2a3b) or alternative 
(C3bBb3b) pathways cleaves C5 into C5a and C5b. C5a remains in the fluid phase 
and C5b associates rapidly with C6 and C7 and inserts into the membrane [92]. 
C5a generated in the lytic pathway has several potent biological activities. It is the 
most potent anaphylatoxin. In addition to the ability to induce an anaphylactic 
shock, C5a intervening in the inflammatory response in causing contraction of the 
muscles, vasodilatation, and the vascularization of vascular permeability. The 
properties of anaphylatoxin C5a may be partially inhibited or controlled after 
cleavage of carboxy-terminal arginine by serum carboxypeptidase leading to the 
generation of C5a-desarg [93]. 
1.4.4.3.1 The structure and functions of C5a 
Anaphylatoxin C5a is a polypeptides molecule that is composed of 74 
amino. NMR spectroscopy proved that the molecule is composed of four helices 
and connected by peptide loops with three disulphide bonds between helix IV and 
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II, III. There is a short 1.5 turn helix on N terminus, but all agonist activity take place 
in the C terminus.C5a is rapidly metabolized by a serum enzyme carboxypeptidase 
B to a 72 amino acid form C5a des-Arg without C terminal arginine [94]. 
Of the three anaphylatoxins, C5a is more potent and binds to at least two 
receptors C5aR (CD88) and C5L2. The functional role of C5L2 is enigmatic. C5a 
is a 74 amino acid peptide with pleiotropic biological functions including smooth 
muscle contraction, vascular permeability, mast cell degranulation, leukocyte 
chemotaxis and attraction (Figure 1.1) [95]. Early studies involving complement 
mediated immune regulation showed that C5a potentiates antibody and antigen-
induced T cell proliferative responses in vitro possibly through activation of T 
helper cells [96]. Direct stimulation of mouse and human dendritic cells by C5a 
activates them as demonstrated by increased expression of MHC class II, 
upregulation of co-stimulatory molecules such as CD80, CD86, CD40 and CD54, 
and secretion of cytokines of Th1 phenotype [97, 98]. C5a-mediated stimulation of 
DCs also decreased intracellular production of cAMP, which is a negative regulator 
of DC activation and function [98]. Furthermore, C5a interaction with C5aR 
activates PI3K, ERK1/2, NF-kB signaling pathways in DCs, which positively 
regulate antigen uptake, presentation and secretion of proinflammatory cytokines 
by DCs [97,98]. C5a was also shown to exhibit both synergistic as well as 
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antagonistic crosstalk with toll like receptors (TLRs) in functional modulation of 
DCs [97,98]. C5a decreased TLR4 mediated IL-12 secretion by DCs, but 
significantly increased secretion of other Th1 cytokines and CXC16 involved in NK 
cell activation. 
C5a-C5aR interactions were shown also to be essential for generation of 
protective anti-viral CD8+ T cells. In contrast, genetic ablation or pharmacologic 
blocking of C5aR signaling predominantly generated of Th2 and regulatory T cell 
responses [99]. Furthermore, previous studies found that blocking C5a-C5aR 
interactions also impaired the ability of immune system to generate memory CD4+ 
T cells [100]. Recent evidences also found that DCs stimulated with recombinant 
C5a showed increased expression of multiple co-stimulatory molecules, migration 
to the draining lymph nodes and strong interaction with antigen-specific naïve T 
cells. 
Besides immunostimulatory properties that promote antigen presentation 
and functional immune responses, C5a also possesses highly inflammatory 
properties.  C5a is known to be the most potent mediator of local and systemic 
inflammatory responses and causes multiple immunological effects such as 
activating and recruiting neutrophils, induce spasmogenesis, increase vascular 
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permeability and stimulate the release of secondary inflammatory mediators from 
a variety of cell types (e.g., leukocytes and macrophages). Anaphylatoxin C5a is 
also a potent chemotactic agent and release at the site of the lesion C5a causes 
the release of histamine by the mast cells, the production of superoxide anions 
and the release of hydrolytic enzymes by the neutrophils and promotes the 
phagocytosis by the macrophages. By increasing the release of toxic proteins and 
oxygenated reagents, C5a also activates eosinophils. Moreover, the stimulation of 
macrophages by C5a results in the secretion of interleukin 1 (101). 
1.4.4.3.2 Development of EP54 and EP67  
C5a consists of highly ordered helical N-terminus (1-63) responsible for 
recognition and binding of C5aR and highly flexible disordered C-terminus (64-74) 
that exists as a finger-like projection from N-terminus (Figure 1.2) core responsible 
for transducing biological signal [102]. Decapeptides possessing the essential 
conformational features of C-terminus region of C5a showed full agonist activity 
compared to natural C5a. Conformationally biased, response-selective agonist of 
C5aR, EP54 (YSFKDMPLaR) was synthesized by amino acid residue modification 
of C-terminus region of C5a (65-74). EP54 retained C5a-like immunostimulatory 
properties as demonstrated by 5% of C5a-like induction of smooth muscle 
contraction but was devoid of C5a-like inflammatory properties as demonstrated 
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by only 0.1% of C5a’s ability to induce mast cell degranulation. The unique 
structural and conformational features were shown to be well accommodated by 
C5aRs on antigen presenting cells such as DCs and macrophages, but not by 
C5aRs expressed on neutrophils. Furthermore, these conformational features 
increase stability of EP54 from proteolytic degradation by serum carboxy-
peptidases. Additional modification of EP54 by introducing N-methylation 
generated EP67, which increased response-selectivity towards C5aR and reduced 
activity towards neutrophils up to 3000-fold compared to EP54 [103].  
1.4.4.3.3 Vaccine Adjuvant Properties of EP54 and EP67  
EP54 and EP67 were successfully used as adjuvants to generate antigen-
specific humoral and cellular immune responses. Mice immunized with EP54 
containing MUC1-constructs generated antibodies with class switched isotype, 
which were able to bind to MUC1- expressing cancer cell lines. EP54 and MUC1-
CTL epitope containing vaccines also generated functional antigen specific 
cytotoxic T cell responses [102]. Mice and rats immunized with EP67-conjugated 
protein vaccines generated Th1-type humoral immune responses. Older mice 
immunized with EP67 conjugated to a model protein antigen ovalbumin were also 
able to generate higher antibody responses and Th1-type isotype switching which 
were not observed when a toll like receptor (TLR) ligand CpG or alum were used 
44 
 
as adjuvants [104]. The vaccine adjuvant properties of EP54 and EP67 in 
generating protective adaptive immune responses were shown demonstrated in 
various animal species (Table 1.2). EP54 and EP67 have shown to increase 
antigen processing and presentation capacity, and induced release of Th1 type 
cytokines by C5aR-bearing APCs [105]. 
Furthermore, EP67 was shown to reduces Methicillin-Resistant 
Staphylococcus aureus (MRSA) skin lesions. Subcutaneous administration of 
EP67 (250 µg), but not inactive scrambled EP67 or PBS vehicle, significantly 
reduced lesion size and recoverable CFU counts in outbred CD1 mice with dermal 
infections of MRSA (TCH1516 USA 300). These host-directed anti-MRSA effects 
are C5aR/CD88-dependent since they were not seen in C5aR knockout mice 
(CD88-/-). EP67 induced the recruitment of essential neutrophils and 
macrophages to the lesion site through cytokine/chemokine release from C5aR-
bearing APCs in the lesion zone [106].  
Moreover, administration of EP67 (200 µg) in the area of a MRSA (USA 300 
LAC) biofilm infection around an implanted subcutaneous catheter resulted in a 
significant reduction of recoverable CFU counts within the biofilm and surrounding 
tissue. This effect was seen within 24 hrs of administration of EP67 and was 
sustained for up to 5 days post-administration. It was also shown that EP67 
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increased the recruitment of macrophages to the biofilm infection and induced the 
release of IL-12p40, CCL5, IL-17, IL-1β, and INFγ in the biofilm. These effects 
were not seen by the administration of inactive scrambled EP67 or vehicle (PBS) 
[107]. 
Furthermore, pulmonary delivery of EP67 was also found to protects against 
sub-lethal and lethal Infections of Influenza A. Intranasal insufflation of EP67 (25 
µg in 30 µL) 24 hrs prior to influenza infection significantly reduced loss of body 
weight upon infection relative to mice that received no EP67 or vehicle (PBS) only. 
Likewise, infected mice that received EP67 (25 µg in 30 µL) 24 hrs post-infection 
showed a significant reduction in the loss of body weight relative to mice that 
received no EP67 or PBS only.  This pulmonary administration of EP67 resulted in 
a significant influx of neutrophils, alveolar macrophages, dendritic cells, and 
natural killer cells in the bronchoalveolar lavage (BAL) fluids of both uninfected and 
infected mice.  BALs from mice treated with EP67 also showed significantly higher 
amounts of IL-6, GM-CSF, KC (the murine equivalent of IL-8), IL1β, IL12p70, and 
MIP-1. These cellular and cytokine/chemokine influxes are consistent with the 
prophylactic and therapeutic effects of EP67 described above as well as the ability 
of EP67 to overcome the inherent immune suppressive effects of influenza 
infection. These effects were not observed in mice administered scrambled EP67 
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of PBS vehicle.  Finally, intranasal insufflation of EP67 (240 µg in 30 µL) 24 hrs 
after administration of a lethal dose of influenza protected all mice (100% survival) 
up to 30 days. All untreated mice were dead 11 days post-infection [108]. The 
results summarized above underscore the capacity of the topochemical features 
expressed in EP67 to be selectively accommodated by C5aRs expressed on APCs 
vs. C5aRs expressed on neutrophils and, consequently, the ability to selectively 
activate C5aR-bearing APCs for the induction of host innate immunity, which 
reduces normal/resistant bacterial and viral infections. Thus, EP67 can be used as 
a template from which can be generated EP67 analogs even more effective in 
C5aR-bearing APC engagement and activation. The availability of such analogues 
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Table 1.1 Clinically licensed immunostimulants (Adapted from [2]) 
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Vaccine Construct Route Immune Response Ref 
Peptide epitope from MUC1 
glycoprotein conjugated to EP54 
i.p. ↑IgG2b, IgG2c and IgM 
Abs  
[102]  
CTL peptide epitope derived from 
Hepatitis B surface Antigen 
(HBsAg) conjugated to EP54  
s.c Ag-specific CD8+ CTL 
responses against murine 
P815S target cells  
 [109] 
Nicotine hapten conjugated to 
EP54 
i.p. Nicotine-specific Abs   [110] 
Methamphetamine (meth) hapten 
conjugated to EP54 
s.c /i.p. Meth-specific Abs in sera  [111]  
OVA conjugated to EP67 i.p. OVA-specific Th1-like Ab 
class switch and OVA-
specific proliferative 
responses in splenocytes  
[112]  
OVA conjugated to EP67 i.p. ↑ Ag-specific humoral  [113]  
rPrp1,a  protein from cell wall of 
coccidioides conjugated to EP67 
i.p. ↑ humoral responses 
compared to alum and 
CpG  
 [113] 
Peptide epitope derived from gp70 
glycoprotein conjugated to EP54 
and EP67 

















Live spores of attenuated vaccine 
strain of Coccidioides posadasii 
conjugated to EP67 
s.c ↑ IgG1, IgG2a, Th1, and 
Th17 immune responses  
[115]  
CTL peptide epitopes from MCMV 
PP89 and M84 conjugated to EP67 
i.n. ↑ CTL responses  
↓ MCMV titers 
[116] 




















2.1 Research Objectives and Hypotheses 
There is an unmet need for safe and efficacious approaches to treat 
infections through the stimulation of systemic and mucosal innate immunity with 
little toxicity. One approach is to stimulate innate immune responses with a safe 
and effective immune stimulatory molecule. Such “host-directed immunotherapy” 
will stimulate the body’s inherent first line of defense against infections while 
exerting few/no mutational pressure on the infecting pathogen. Our group 
previously has shown the potential of host-directed immunotherapy against viral 
infections in mice by the administration of our lead immune stimulatory candidate 
EP67. 
The decapeptide EP67 is a novel host-derived adjuvant based on the C-
terminal of C5a that selectively activates antigen presenting cells (APCs)- 
monocytes, macrophages, and dendritic cells over neutrophils. In contrast to 
C5a65-74 from the C5a parent molecule, EP67 has topographical features that are 
well accommodated by C5aRs expressed on (APCs), but not C5aRs neutrophils. 
Thus, EP67 induces host innate immune responses against normal and resistant 
infections via engagement of C5aR-bearing APCs with little/no inflammatory side-
effects associated with the direct activation of neutrophils. 
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The Pro residue at position 7 (Pro7) is critical for the potency and selectivity 
of EP67. It was placed in this position to force an extended conformation at the 
carbonyl carbon between the  and  bonds in the Met backbone to its N-
terminus, a feature that was found to be biologically important from SAR studies 
with the previous analog of EP67, EP54. The Pro residue, however, undergoes 
cis/trans isomerization that leads to conformers of EP67 in solution, making it 
unclear whether cis/trans isomerization is important to the biological properties of 
EP67 or if one conformer is more effective than the other. What is clear is that the 
conformational influence of Pro at this position is important for the activity and bio-
selectivity of EP67. Our long-term goal is to increase the potency and efficacy of 
EP67 to improve host-directed immunotherapy and vaccine applications. The 
overall objective of this proposal is to generate analogs of EP67 with increased 
potency, efficacy, and bio-selectivity. Our central hypothesis is that replacing Pro 
in position 7 with structurally diverse residues that are likely to shift the cis/trans 
conformer equilibrium or lock the conformation in either a cis or trans orientation 




2.2 Specific Aims 
Specific Aim 1. Synthesize a series of EP67 analogs with residue substitutions 
for Pro at position 7. As noted above, our goal is to generate a series of EP67 
analogs to better understand the conformational influence of Pro in the Met-Pro-
MeLeu triad region of EP67 and to increase the structural diversity within this 
biologically important core of EP67 with the objective of increasing the potency 
and bio-selectivity of this unique innate immune stimulatory decapeptide. 
Specific Aim 2. Determine analog potency and bio-selectivity in C5aR-bearing 
human phagocytes (monocytes, monocytes-derived macrophages (M0-MDM), 
monocytes-derived immature DCs (MDDC), and C5aR-bearing human 
neutrophils. EP67 analogs generated in Aim 1 will be assessed for their potency 
to C5aRs on human monocytes, M0-MDM, MDDC and neutrophils, as measured 
by cytokine release (IL-1β, IL-6, and TNF-α) from monocytes, M0-MDM, MDDC 
and myeloperoxidase (MPO) release from neutrophils, and from these potency 























3.1 Peptide synthesis, purification, and characterizations 
With the assistance of an AAPPTEC Apex 396 Synthesizer, all peptides 
were assembled on preloaded Fmoc-Arg(pbf)-Wang resin using Fmoc-amino acid 
derivatives and N-(dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-
ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HATU) in 
the presence of excess DIEA. Peptides were cleaved from the resin and freed of 
sidechain protecting groups by stirring the peptide-resin in a mixture of TFA 
(87.5%), phenol (5%), water (5%), and triisopropylsilane (2.5%) for 2h at room 
temperature [117,118]. All peptides were subjected to analytical reversed-phase 
HPLC employing three different columns under the same gradient elution 
conditions. The three columns were an ACE 5 C18-300 column (250 x 4.6 mm, 5 
µm, 300 Å pore size, catalog number ACE-221-2546), ACE 5 Phenyl-300 column 
(250 x 4.6 mm, 5 µm, 300 Å pore size, catalog number ACE-225-2546) and ACE 
5 CN-300 column (250 x 4.6 mm, 5 µm, 300 Å pore size, catalog number. ACE-
224-2546) from MAC-MOD Analytical Inc. (Chadds Ford, PA). Solvent A was water 
containing 0.1% trifluoroacetic acid (TFA, v/v) and solvent B was a mixture of 
acetonitrile and water (3/2, v/v) containing 0.1 % TFA. Peptides were eluted from 
the columns by increasing the percentage of solvent B from 5 to 100% over 50 
minutes and column effluent was continuously monitored at 214 nm. Peptide 
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masses were obtained from the Mass Spectrometry and Proteomics Core Facility 
at the University of Nebraska Medical Center. Masses were measured on an 
Orbitrap Fusion Lumos from ThermoScientific (Waltham MA) and with ≤ 0.5 ppm 
error. Amino acid compositions of all peptides were provided by the Protein 
Structure Core Facility at the University of Nebraska Medical Center. Samples 
were subjected to vapor-phase hydrolysis in constant boiling 6M hydrochloric acid 
for 24 hours prior to being loaded on to a Hitachi 8800 Amino Acid Analyzer. 
3.2  De novo peptide structures 
PEP-FOLD was used to generate the initial conformation of C5a65-
74. Analogs of C5a65-74 were generated in YASARA and refined for 500 ps using 
the built-in md_refine macro. Each refined structure was then used in a 50 ns 
molecular dynamics (MD) simulation. All molecular dynamics simulations and post-
analysis used Desmond as bundled with the Schrodinger software suite. Each 
peptide was placed in a cubic box with periodic boundaries. No dimension of the 
box was allowed closer than 12 Angstroms to allow the peptides room to unfold. 
The box was filled with TIP4P water and neutralized by adding the appropriate Na+ 
or Cl- ions. Salt concentration in the box was set to 0.05 M NaCl. All simulations 
first used Schrodinger’s built in relaxation protocol before the main MD run. The 
main 50 ns MD run was an NPT ensemble with temperature at 298K and pressure 
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at 1 atm. Noose-Hoover chain and Martyna-Tobias-Klein were the thermostat and 
barostat methods, respectively. The average structure of the major cluster of each 
trajectory was then extracted for comparison in YASARA [119,120]. 
3.3 Isolation of human monocytes and neutrophils from human whole blood 
Fresh whole blood [1 unit = 450 mL] was drawn from human healthy male 
donors (aged 19–40 years) into vacutainer bags (Research Innovative, USA) 
containing EDTA. CD14+ monocytes [165 mL of blood/donor] were isolated by 
MACS® technology using CD14 MicroBeads (Miltenyi Biotec, Germany) according 
to the manufacturer's protocol. Isolated monocytes [1x106 cells/well] were cultured 
into 24-well plates, and allowed to adhere [2 hrs] in complete culture medium 
(CCM) (RPMI 1640, 2 mM L-glutamine, 1% autologous plasma, 1 mM sodium 
pyruvate, 0.1 mM non-essential amino acids, 1x vitamins, 100 U/mL penicillin G, 
100 g/mL streptomycin sulfate (Invitrogen, Carlsbad, CA) [1 mL/well] and 
incubated at 37 °C and 5% CO₂. Non-adherent cells were discarded, and the 
adherent cells were washed carefully twice with sterile D-PBS (“PBS” without Ca2+ 
or Mg2+, GE Healthcare Life Sciences: SH30028.02) [1 mL] [120,121].  
Neutrophils were also isolated from same donors [10 mL of blood/donor] 
using the MACSxpress® Whole Blood Neutrophil Isolation Kit, a MACSmix™ Tube 
Rotator, and a MACSxpress Separator (Miltenyi Biotec, Germany) according to the 
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manufacturer's protocol. Isolated neutrophils [1x106 cells/well] were cultured into 
24-well plates in CCM [1 mL] and incubated at 37 °C and 5% CO₂. Non-adherent 
cells were discarded, and the adherent cells were washed carefully twice with 
sterile D-PBS [123]. The purity of the isolated monocyte and neutrophil was 
determined by labeling cells with CD14- PE-Vio615, CD-15APC, and CD-16PE 
human antibodies (Miltenyi Biotec, Germany) before and after separation, and 
analyzed by flow cytometry. Briefly, isolated cells [1x106] were resuspended in cell 
staining buffer (BD Biosciences) [100 µL] and indicated antibodies [5 µL/each 
antibody]. Cells were mixed and incubated in the dark in the refrigerator [2−8 °C, 
10 min.]. Then, cells were washed by adding staining buffer [1 mL] and pelleted 
[300 RCF, RT, 10 min.]. The supernatant was completely aspirated, and cell pellets 
were resuspended in FACS staining buffer [0.5 mL] for analysis by cytometry. Cells 
were analyzed on a BD LSR II flow cytometer (Becton and Dickinson, La Jolla, CA) 
with BD High Throughput Sampler. Flow cytometer was compensated using single 
stained cells, maximum number of events were acquired and analyzed by FlowJo 
software (Tree Star, Ashland, OR, USA) [124,125]. 
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3.4 Generate unpolarized human monocyte-derived macrophages (M0-
MDM), and human monocyte-derived dendritic cells (MDDC) 
Generation of unpolarized human monocyte-derived macrophages (M0-
MDM) was done by culturing monocytes [1×10⁶ cells/well] in CCM [1 mL] 
containing recombinant human M-CSF (Miltenyi Biotec) [50 ng/mL] in 24 well 
plates. On day 3, half media [0.5 mL] from each well was carefully removed and 
replenished with CCM containing rhM-CSF. After the differentiation, the cell 
supernatants were completely removed by gentle aspiration and cells were 
washed once with warm sterile PBS [126-128]. 
To generate human monocytes-derived immature dendritic cells (MDDC), 
isolated monocytes [1×10⁶ cells/well] were cultured in CCM [1 mL] supplemented 
with recombinant human IL-4 [50 ng/mL] and recombinant human GM-CSF [160 
ng/mL] (Miltenyi Biotec) in 24-well culture dishes. On days 3 and 6, half of the 
volume [0.5 mL] was gently aspirated from each well and replenished with CCM 
containing GM-CSF and IL-4 [128-130]. The morphology of differentiated cells 
(macrophages as well as immature Mo-DCs) were analyzed by placing cells in a 
24-well plate and allowed to sediment. Images of the cells were captured using a 
light microscope with phase-contrast at a 400× magnification.  
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3.5  Determine the potency of EP67 analogs 
Analog potency was determined by measuring the half-maximal effective 
concentration (EC50). EC50 values for each analog were determined in two 
separate assays: cytokine release from human mononuclear phagocytes (human 
monocytes, M0-MDM, and MDDC) and myeloperoxidase (MPO) release from 
human neutrophils. Full dose-response curves were generated in each 
experiment, and the EC50 values were determined. Briefly, monocytes, M0-MDM, 
and MDDC [1x106 cells/well] were incubated in the presence of serial 
concentrations of C5a desArg, EP54, EP67, and EP67 analogs in standard cell 
culture conditions for 24 hrs.  Supernatants were collected and assayed for the 
presence and amount of the IL-1β, IL-6, and TNF-α (BioLegend, USA) using 
standard ELISA methods [102,131].  
In human neutrophils, the release of the proteolytic enzyme MPO was 
measured. Briefly, neutrophils were incubated in the presence of serial 
concentrations of C5a desArg, EP54, EP67, and EP67 analogs in standard cell 
culture conditions for 24 hrs. Supernatants were collected and assayed for the 
presence and amounts of MPO using standard ELISA [103,131].   
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3.6  Determine the bio-selectivity of EP67 analogs 
Analog selectivity for cytokine release (IL-6, and TNF-α) from phagocytes 
cells (monocytes, M0-MDM, and MDDC) vs. MPO release from neutrophils were 
determined by the following equation:  
Selectivity = antilog[(-∆phagocytes) – (-∆neut)] 
, where ∆ is the log potency ratio (pD2 C5a – pD2 analog) and pD2 = –logEC50.  The 
“selectivity” of natural C5a desArg were set at value of 1 using this equation since 
it is equipotent in both cytokine release from monocytes and MPO release from 
neutrophils. Thus, differences in the potencies between these two C5aR-bearing 
cells can be assessed relative to C5a desArg; i.e., the greater the value from the 
above equation, the greater the selectivity relative to C5a desArg. This is the 
pharmacologically accepted means of determining selectivity between two 
compounds and was used by us to determine the selectivity of EP67 for 
engagement and activation of C5aR-bearing phagocytes over that of C5aR-
bearing neutrophils (131). 
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3.7 Compare the IL-6 and TNF-α cytokine release rates from human 
monocytes, M0-monocyte-derived macrophages, and immature 
monocyte-derived dendritic cells. 
Human monocytes (MC), M0-monocyte-derived macrophages (M0-
MDM), and immature monocyte-derived dendritic cells (MDDC) were prepared 
from the whole blood of healthy, young human adult male donors. Cell types 
were treated with the calculated EC50 of human C5a desArg pooled from the 
blood of multiple donors (black closed circles), 1st-generation EP54 (black 
closed squares), 2nd-generation EP67 (black closed triangles), [Cha7]EP67 
(red open circles), [Leu8]EP67 (green open squares), or [Cha7, Leu8]EP67 
(blue open triangles). At the indicated time points, average concentrations of 
IL-6 or TNF-α released into cell culture media by human monocytes, M0-MDM, 

























4.1 Replacing Pro7 with cyclohexylalanine and/or N-methyl Leu8 with Leu 
selectively affects the potency and efficacy of EP67 in human 
mononuclear phagocytes 
We originally proposed that Pro7nme-Leu8 increases the potency and 
selective activation of mononuclear phagocytes vs. neutrophils vs. EP54 by 
extending the peptide backbone. Thus, we wanted to identify amino acid 
substitutions that would eliminate cis/trans isomerization of EP67 while still 
extending the peptide backbone. We hypothesized that substituting an amino acid 
that eliminates cis/trans isomerization and has a bulky side chain such as 
cyclohexylalanine (Cha) will extend the peptide backbone of EP67 to a similar 
extent as Pro7nme-Leu8 without adversely affect potency and efficacy. RMSD 
traces from de novo peptide structure prediction showed long periods of low RMSD 
to the major cluster, suggesting C5a65-74 maintains an alpha-helical backbone 
conformation throughout most of the simulation (Figure 4.1). In contrast, although 
[Cha7Leu8] EP67 is masked in the major cluster view, RMSD traces indicate that 
amino acid substitutions introduced to EP67 and EP67 analogs greatly increase 
the flexibility of C5a65-74. This increased flexibility is more similar to the disordered 
structure of C5a65-74 observed by MMR when part of native C5a, although a short 
helix was observed. The similarity between C5a65-74 and [Leu8] EP67 RMSD traces 
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suggests [Leu8] EP67 best preserves the predicted alpha-helical backbone of 
C5a65-74. We hypothesized that nme would not be required to extend the peptide 
backbone with Cha  
To determine if replacing Pro7 and/or N-methyl Leu8 with amino acids that 
induce similar structural changes will affect the potency and efficacy of EP67 in 
human mononuclear phagocytes, we first replaced Pro7 with Cha ([Cha7]EP67), 
nme-Leu8 with native Leu ([Leu8]EP67), or Pro7 and nme-Leu8 with Cha and native 
Leu, respectively ([Cha7Leu8]EP67) (Table 4.1), determined purity (Table 4.2) 
(Figure 4.2) and molecular mass (Table 4.3) (Figure4.3), and confirmed the 
amino acid sequence (Table 4.4) of each peptide. We then prepared human 
CD14+ / CD14+CD16+ monocytes (MC), unpolarized human monocyte-derived 
macrophages (M0-MDM), and human monocyte-derived dendritic cells (MDDC) 
from the whole blood of healthy, human adult male donors (Figure 4.4) and 
compared dose-dependent secretion of IL-1β, IL-6, and TNF-α after treating with 
pooled human C5a desArg (parent molecule), EP54 (1st generation ADI), EP67 
(2nd-generation ADI), or EP67 analogs for 24 h (Figure 4.5). We used “classical” 
CD14HI MC because they represent 85% to 95% of human monocytes and will 
include the “intermediate subset” CD14+CD16+ MC and potentially the “non-
classical” CD14LOCD16HI MC 1, unpolarized M0-MDM (Day 6 MCF) because they 
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are similar to tissue resident macrophages from healthy tissues, and MDDC (Day 
7 GM-CSF/IL-4). Mononuclear phagocytes (monocytes, macrophages, and 
dendritic cells) are critical immune sensors in the body that play a key role in 
initiating and guiding innate and adaptive immunity. Acute inflammation augments 
innate and adaptive immune responses and is driven by the secretion of three 
major proinflammatory cytokines: IL-1β, IL-6, and TNF-α. We compared dose-
dependent secretion of IL-1β, IL-6, and TNF-α because they are the major early 
pro-inflammatory cytokines that drive acute inflammation in support of innate and 
adaptive immune responses and are, consequently, good surrogate markers for 
the activation of mononuclear phagocytes. 
Sigmoidal dose-responses curves were observed for IL-1β secretion from 
MC, M0-MDM, and MDDC over the concentration range of C5a desArg (Figure 
4.6), whereas IL-1β was not detected after treatment with up to 1 mM EP54, EP67, 
or EP67 analogs (not shown). In contrast to IL-1β, sigmoidal dose-response curves 
were observed for IL-6 and TNF-α secretion from MC, M0-MDM, and MDDC over 
the concentration ranges of C5a desArg (black circles), EP54 (black squares), 
EP67 (black triangles), and EP67 analogs (colored open symbols) (Figure 4.5). 
This suggests the current ADI do not stimulate the secretion of one or more 
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cytokines and, possibly, chemokines from human mononuclear phagocytes that 
are normally stimulated by the C5a/C5a desArg parent molecule. 
The EC50 for EP67 (Figure 4.7 A, black triangles) ranged from 14.6- (TNF-
α from MC) to 89.5-fold greater (IL-6 from MDDC) than C5a desArg (Figure 4.7 A, 
black circles) (Table 4.5). Furthermore, the EC50 for EP67 (Figure 4.7 A, black 
triangles) was similar to the EC50 for EP54 (Figure 4.7 A, black squares), with the 
exception of TNF-α secretion from MC (35% less) (121 ± [-0.2,+0.3] [95% CI] vs. 
186 [-0.2,+0.3] nM) and IL-6 secretion from M0-MDM (47% less) (167 ± [-0.3,+0.3] 
[95% CI] vs. 317 [-0.9,+1] nM) (Table 4.5). The EMAX for EP54 ranged from 24 to 
47% lower (Figure 4.7 B, black squares) than pooled human C5a desArg (Figure 
4.7 B, black circles), whereas and the EMAX for EP67 (Figure 4.7 B, black triangles) 
ranged from 6 to 27% lower depending on the cytokine and mononuclear 
phagocyte (Table 4.5). Thus, EP54 and EP67 are both generally partial agonists 
for activating human mononuclear phagocytes. The EMAX for EP67 (Figure 4.7 B, 
black triangles) was 23.6% to 34% greater than the EMAX for EP54 (Figure 4.7 B, 
black squares) also depending on the cytokine and mononuclear phagocyte. Thus, 
the potency of EP67 is similar or greater than EP54 depending on the secreted 
cytokine and human mononuclear phagocyte, whereas the efficacy of EP67 for IL-
6 and TNF-α secretion is greater than EP54 in human mononuclear phagocytes. 
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[Cha7]EP67 (Figure 4.7 A, red open circles) did not affect the EC50 of EP67 
(Figure 4.7 A, black triangles) for IL-6 and TNF-α from MC, decreased EC50 for IL-
6 (29%) but not TNF-α from M0-MDM, and did not affect the EC50 for IL-6 and TNF-
α from MDDC. In contrast, [Leu8]EP67 (Figure 4.7 A, green open triangles) did not 
affect the EC50 for IL-6 and TNF-α from MC, M0-MDM, or MDDC. In contrast, 
[Cha7Leu8]EP67 (Figure 4.7 A, blue open triangles) did not affect the EC50 for IL-
6 and TNF-α from MC, decreased the EC50 for IL-6 (31%) without affecting the 
EC50 for TNF-α from M0-MDM, and did not affect the EC50 for IL-6 but decreased 
the EC50 for TNF-α (39%) from MDDC. Thus, [Cha7]EP67 selectively increases 
potency in M0-MDM without affecting potency in MC or MDDC, [Leu8]EP67does 
not affect potency in MC, M0-MDM, or MDDC, and [Cha7, Leu8] selectively 
increases potency in M0-MDM and MDDC without affecting potency in MC 
compared to EP67. 
[Cha7]EP67 (Figure 4.7 B, red open circles) did not affect EMAX of EP67 
(Figure 4.7 B, black triangles) for IL-6 but increased EMAX for TNF-α (9.5%) from 
MC and decreased EMAX for IL-6 and TNF-α from M0-MDM (9.5%, 16%) and 
MDDC (5.2%, 16.6%). [Leu8]EP67 (Figure 4.7 B, green open squares) decreased 
EMAX for IL-6 (9.3%) without affecting EMAX for TNF-α from MC, did not affect EMAX 
for IL-6 but decreased EMAX for TNF-α (23%) from M0-MDM, and, unexpectedly, 
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greatly increased EMAX for IL-6 and TNF-α from MDDC (41%, 45%) to levels similar 
(IL-6) or greater (TNF-α) than C5a desArg (Figure 4.7 B, black circles). In contrast, 
[Cha7Leu8]EP67 (Figure 4.7 B, blue open triangles) did not affect EMAX for IL-6 
and TNF-α from MC, but decreased EMAX for IL-6 and TNF-α from M0-MDM (21%, 
21%) and MDDC (16%, 10%), respectively. Thus, [Cha7]EP67 selectively 
increases efficacy in M0-MDM and MDDC, [Leu8]EP67 selectively decreased 
efficacy in MC and M0-MDM but significantly increases efficacy in MDDC, whereas 
and [Cha7, Leu8]EP67 does not affect efficacy in MC but decreases in M0-MDM 
and MDDC compared toEP67.  
As a whole, these results indicate that, compared to EP67, (i.) [Cha7]EP67 
does not affect potency but selectively increases efficacy in MC, selectively 
increases potency but decreases efficacy in M0-MDM, and does not affect potency 
but decreases efficacy in MDDC (ii.) [Leu8]EP67 does not affect potency in MC, 
M0-MDM, or MDDC but selectively decreases efficacy in MC and M0-MDM and 
greatly increases efficacy in MDDC and (iii.) [Cha7Leu8]EP67 does not affect 
potency or efficacy in MC, selectively increases potency but decreases efficacy in 
M0-MDM, and selectively increases potency but decreases efficacy in MDDC. 
Thus, replacing Pro7 with cyclohexylalanine and/or N-methyl Leu8 with Leu affects 
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the potency and efficacy of EP67 depending on the human mononuclear 
phagocyte and secreted cytokine. 
4.2  Replacing Pro7 with Cha and/or nme-Leu8 with Leu does not affect EP67 
potency in human neutrophils but selectively decreases efficacy  
To determine if replacing Pro7 with Cha and/or nme-Leu8 with Leu affects 
the potency and efficacy of EP67 in human neutrophils (NP), we isolated 
neutrophils from the whole blood of healthy, young human adult male donors by 
using MACSxpress® Whole Blood Neutrophil Isolation Kit, a MACSmix™ Tube 
Rotator, and a MACSxpress Separator (Miltenyi Biotec, Germany) (Figure 4.4) 
then compared dose-dependent secretion of myeloperoxidase (MPO) from NP 
after treating with pooled human C5a desArg, EP54, EP67, or EP67 analogs for 
24 h (Figure 4.8). Sigmoidal dose-responses curves were observed for MPO 
secretion from NP over the concentration ranges of C5a desArg, EP54, EP67, and 
EP67 analogs (Figure 4.8 A). 
The EC50 for EP54 (Figure 4.8 B, black squares) was 3000-fold greater 
than C5a desArg (7 ± 1 nM [95% CI] vs. 21 [-3,+4] µM) in NP, whereas the EC50 
for EP67 (Figure 4.8 B, black triangles) was 22,857-fold greater than C5a desArg 
(Figure 4.8 B, black circles) (7 ± 1 nM [95% CI] vs. 160 [-17,+20] µM) (Table 4.6). 
Furthermore, the EMAX for EP54 (Figure 4.8 C, black squares) was 1.7-fold less 
77 
 
than C5a desArg (5.6 ± 0.2 [95% CI] vs. 9.3 ± 0.3 ng/mL), whereas the EMAX for 
EP67 (Figure 4.8 C, black triangles) was 2.7-fold less than C5a desArg (3.5 ± 0.1 
[95% CI] vs. 9.3 ± 0.3 ng/mL) (Table 4.6). The EC50 for EP67 was also 3-fold 
greater than EP54 (160 [-17,+20] [95% CI] vs. 21 [-3,+4] µM) and the EMAX was 
1.6-fold less than EP54 (3.5 ± 0.1 [95% CI] vs. 5.6 ± 0.2 ng/mL) (Table 4.6). Thus, 
consistent with previous studies (131), the potencies and efficacies of EP54 and 
EP67 are well below human C5a desArg and the potency and efficacy of EP67 is 
less than EP54 in human neutrophils. 
None of the EP67 analogs (Figure 4.8 B, colored open symbols) affected 
the EC50 for MPO secretion from NP compared to EP67 (Figure 4.8 B, black 
triangle). In contrast, [Cha7]EP67 (Figure 4.8 C, red open circle) and 
[Cha7Leu8]EP67 (Figure 4.8 C, blue open triangle) decreased EMAX for MPO 
secretion by 21% and 24%, respectively (Table 4.6), whereas [Leu8]EP67 (Figure 
4.8 C, green open square) did not affect the EMAX compare to EP67 (Figure 4.8 C, 
black triangle). Thus, replacing Pro7 with cyclohexylalanine and/or N-methyl Leu8 
with Leu has no effect on the potency but selectively decreases the efficacy of 
EP67 in human neutrophils. 
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4.3 Replacing Pro7 with Cha and/or nme-Leu8 with Leu does not affect 
selective activation of human mononuclear phagocytes over human 
neutrophils 
To determine if replacing Pro7 with Cha and/or nme-Leu8 with Leu 
affects the selective activation of human mononuclear phagocytes over human 
neutrophils, we compared the ability of EP54, EP67, or EP67 analogs vs. 
pooled human C5a desArg to selectively stimulate secretion of IL-6 or TNF-α 
from human monocytes (MC), unpolarized monocyte-derived macrophages 
(M0-MDM), and monocyte-derived dendritic cells (MDDC) over secretion of 
myeloperoxidase (MPO) from human neutrophils (NP) 24 h after treatment 
(Figure 4.9). Selectivities of EP67 (Figure 4.9, black triangles) for stimulating 
MC, M0-MDM, and MDDC over NP were 9- to 15-fold greater than EP54 
(Figure 4.9, black squares) depending on cytokine and mononuclear 
phagocyte. EP67 selectivity for stimulating human mononuclear phagocytes 
over human neutrophils is greater than EP54. 
None of the EP67 analogs (Figure 4.9, colored open symbols) affected 
selectivities for stimulating IL-6 or TNF-α secretion from MC (Figure 4.9 A), 
M0-MDM (Figure 4.9 B), or MDDC (Figure 4.9 C) over stimulating the 
secretion of MPO from NP compared to EP67 (Figure 6C, black triangles) 
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(Table 4.7). Thus, replacing Pro7 with cyclohexylalanine and/or N-methyl Leu8 
with Leu does not affect the selective activation of human mononuclear 
phagocytes over human neutrophils by EP67. 
4.4  Replacing Pro7 with Cha and/or nme-Leu8 from the structure of EP67 
does not affect kinetics of cytokine release from human mononuclear 
phagocytes.  
To next determine if replacing Pro7 with Cha and/or nme-Leu8 with Leu 
affects the kinetics of cytokine release from human mononuclear phagocytes, we 
compared the release of IL-6 and TNF-α from human monocytes, M0-MDM, and 
MDDC 24 and 48 h after treatment with the EC50 of [Cha7,Leu8]EP67, human 
C5a desArg, EP54, or EP67 (Figure 4.10). C5a desArg (black bars) had the 
highest levels of IL-6 and TNF-α release after 24 h, whereas [Cha7, Leu8] EP67 
(red bars), EP54 (green bars), and EP67 (blue bars) had the highest levels after 
48 h. Thus, replacing Pro7 with Cha and/or nme-Leu8 with Leu from the structure 







Figure 4.1 De novo structure of C5a desArg, EP54, EP67, and EP67 analogs. 
PEP-FOLD was used to generate the initial conformation of C5a65-74.  Analogs of 
C5a65-74 were generated in YASARA and refined for 500 ps using the built-in 
md_refine macro. Each refined structure was then used in a 50 ns molecular 
dynamics (MD) simulation. All molecular dynamics simulations and post-analysis 
used Desmond as bundled with the Schrodinger software suite. Each peptide was 
placed in a cubic box with periodic boundaries. No dimension of the box was 
allowed closer than 12 Angstroms to allow the peptides room to unfold. The box 
was filled with TIP4P water and neutralized by adding the appropriate Na+ or Cl- 
ions. Salt concentration in the box was set to .05 M NaCl. All simulations first used 
Schrodinger’s built in relaxation protocol before the main MD run. The main 50 ns 
MD run was an NPT ensemble with temperature at 298K and pressure at 1 atm. 
Noose-Hoover chain and Martyna-Tobias-Klein were the thermostat and barostat 
methods, respectively. The average structure of the major cluster of each trajectory 




Cha = cyclohexylalanine. Peptides were subjected to analytical reversed-phase 
HPLC employing three different columns under the same gradient elution 
conditions: an ACE 5 C18-300 column (250 x 4.6 mm, 5 µm, 300 Å pore size, 
catalog number ACE-221-2546), an ACE 5 Phenyl-300 column (250 x 4.6 mm, 5 
µm, 300 Å pore size, catalog number ACE-225-2546), or an ACE 5 CN-300 column 
(250 x 4.6 mm, 5 µm, 300 Å pore size, catalog number. ACE-224-2546) from MAC-
MOD Analytical Inc. (Chadds Ford, PA). Solvent A was ddH2O containing 0.1% 
trifluoroacetic acid (TFA, v/v) and solvent B was a mixture of acetonitrile and 
ddH2O (3/2, v/v) containing 0.1 % TFA. Peptides were eluted from the columns by 
increasing the percentage of solvent B from 5 to 100% over 50 minutes while 









Figure 4.3 Mass chromatograms of EP67 and EP67 analogs. Cha = 
cyclohexylalanine. Masses were measured on an Orbitrap Fusion Lumos from 
ThermoScientific (Waltham MA) and with ≤ 0.5 ppm error. EP67: HRMS-ESI (m/z): 
[M + H]+ calculated for (C57H88N14O15S + H), 1241.6352; found 1241.6350. 
[Cha7]EP67: HRMS-ESI (m/z): [M + H]+ calculated for (C61H96N14O15S + H), 
1297.6978; found 1297.6984. [Leu8]EP67: HRMS-ESI (m/z): [M + H]+ calculated 
for (C56H86N14O15S + H), 1227.6196; found 1227.6196. [Cha7Leu8]EP67: HRMS-








Figure 4.4 Experimental design for determining immunostimulant activity in 
human mononuclear phagocytes and neutrophils. Monocytes (MC) and 
neutrophils (NP) were isolated from the whole blood of healthy, human adult male 
donors (19 to 59 y.o.) using Miltenyi magnetic anti-CD14 MicroBeads and 
MACSxpress® Whole Blood Neutrophil Isolation Kits, respectively. Isolated NP 
were plated for 2 h before treatment, whereas isolated CD14+/CD14+CD16+ MC 
were plated for 2 h before immunostimulant treatment or treated after 
differentiation into M0-monocyte-derived macrophages (M0-MDM) (human GM-
CSF 6 d) or immature monocyte-derived dendritic cells (MDDC) (human GM-
CSF/Il-4 for 7 d). For potency studies, cells were incubated with increasing 
concentrations of the indicated immunostimulant for 24 h and concentrations of IL-
6 and TNF-α [MC, M0-MDM, MDDC] or myeloperoxidase (MPO) [NP] released 
into cell culture media was determined by ELISA. For kinetic studies, MC, M0-
MDM, and MDDC were incubated with the EC50 of the indicated immunostimulant 
in the respective cell type and concentrations IL-6 and TNF-α released into cell 











Figure 4.5 Dose response of IL-6 and TNF-α secretion from human 
monocytes, M0-monocyte-derived macrophages, and immature monocyte-
derived dendritic cells after treatment with human C5a desArg, EP54, EP67, 
or EP67 analogs for 24 h. Human monocytes (MC), unpolarized M0-monocyte-
derived macrophages (M0-MDM), and immature monocyte-derived dendritic cells 
(MDDC) were prepared from the whole blood of healthy, young human adult male 
donors (Fig. 4.4). Cells were then treated with increasing concentrations of human 
C5a desArg pooled from the blood of multiple donors (closed black circles), 1st-
generation EP54 (closed black squares), 2nd-generation EP67 (closed black 
triangles), [Cha7]EP67 (open red circles), [Leu8]EP67 (open green squares), or 
[Cha7, Leu8]EP67 (open blue triangles). After 24 h, average concentrations (± SD) 
(n=2 replicates from 3 blood donors) of IL-6 or TNF-α secreted into the cell culture 
media of human monocytes (A & D), M0-MDM (B & E), or MDDC (C & F) were 
determined by ELISA and fit with a four-parameter dose-response curve where 








Figure 4.6 Dose response of IL-1β secretion from human monocytes, 
uncommitted M0-monocyte-derived macrophages, and immature monocyte-
derived dendritic cells after treatment with human C5a desArg for 24 h. 
Human monocytes (MC), M0-monocyte-derived macrophages (M0-MDM), and 
immature monocyte-derived dendritic cells (MDDC) were prepared from the whole 
blood of healthy, young human adult male donors .Cells were then treated with 
increasing concentrations of human C5a desArg pooled from the blood of multiple 
donors. After 24 h, average concentrations (± SD) (n=2 replicates from 3 donors) 
of IL-1β in the cell culture media of human monocytes (black circles), M0-MDM 
(black squares), or MDDC (black triangles) were determined by ELISA and fit with 
a four-parameter dose-response curve where Y=Min + (xHillslope)*(Max-
Min)/(xHillSlope + EC50HillSlope). IL-1β release was not observed from MC, M0-MDM, 
or MDDC after treatment with up to 1 mM of EP54, EP67, or EP67 analogs (not 
shown). Values calculated from dose response curves. n = number of healthy, 
young human adult male blood donors. aEC50 = average molar peptide 
concentration that stimulated 50% maximum secretion of indicated cytokine 
[±95%CI]. bEMAX = average maximum mass concentration of secreted cytokine 





Figure 4.7 Comparison of potencies and efficacies for IL-6 and TNF-α 
secretion from human mononuclear phagocytes after treatment with human 
C5a desArg, EP54, EP67, or EP67 analogs for 24 h. Average (A) potencies 
(EC50) and (B) efficacies (EMAX) ±95% CI for IL-6 (left Y-axis) and TNF-α (right Y-
axis) were calculated from dose response curves of IL-6 and TNF-α secretion from 
human monocytes (MC), M0-monocyte-derived macrophages (M0-MDM), and 
monocyte-derived dendritic cells (MDDC) after treatment for 24 h. 0.05 level of 
statistical difference vs. aEP67 (black triangles) for the indicated cytokine in the 








Figure 4.8 Dose response of myeloperoxidase release from human 
neutrophils after treatment with human C5a desArg, EP54, EP67, or EP67 
analogs for 24 h. (A) Human neutrophils (NP) were prepared from the whole blood 
of healthy, young human adult male donors (18 to X y.o.) (Figure 4.4). NP were 
then treated with increasing concentrations of human C5a desArg pooled from the 
blood of multiple donors (black circles), 1st-generation EP54 (black squares), 2nd-
generation EP67 (black triangles), [Cha7]EP67 (open red circles), [Leu8]EP67 
(open green squares), or [Cha7, Leu8]EP67 (open blue triangles). After 24 h, 
average concentrations (± SD) (n=2 replicates from 3 blood donors) of 
myeloperoxidase (MPO) released into cell culture media were determined by 
ELISA and fit with a four-parameter dose-response curve where Y=Min + 
(xHillslope)*(Max-Min)/(xHillSlope + EC50HillSlope). Average (B) potencies (Log EC50) and 
(C) efficacies (EMAX) ±95% CI for MPO secretion were calculated from the MPO 












Figure 4.9. Comparison of selective activation of human mononuclear 
phagocytes vs. human neutrophils after treatment with human C5a desArg, 
EP54, EP67, or EP67 analogs for 24 h. Average selectivities ± propagated 95% 
CI for stimulating the secretion of IL-6 or TNF-α from human (A) MC, (B) M0-MDM, 
or (C) MDDC over secretion of MPO from human neutrophils (NP) were calculated 













Figure 4.10 Comparison of IL-6 and TNF-α cytokine release rates from human 
monocytes, M0-monocyte-derived macrophages, and immature monocyte-
derived dendritic cells after treatment with C5a desArg, EP54, EP67, or EP67 
analogs. Human monocytes (MC), M0-monocyte-derived macrophages (M0-
MDM), and immature monocyte-derived dendritic cells (MDDC) were prepared 
from the whole blood of healthy, young human adult male donors. Cell types were 
then treated with the calculated EC50 of human C5a desArg pooled from the blood 
of multiple donors (black closed circles), 1st-generation EP54 (black closed 
squares), 2nd-generation EP67 (black closed triangles), [Cha7]EP67 (red open 
circles), [Leu8]EP67 (green open squares), or [Cha7, Leu8]EP67 (blue open 
triangles). At the indicated time points, average concentrations (± SD) (n=2 
replicates from 3 donors) of IL-6 or TNF-α released into cell culture media by 
























   Tyr01Ser02Phe03Lys04Pro05Met06Pro07Leu08(d-
Ala)09Arg10 
EP67 1241.6 
   Tyr01Ser02Phe03Lys04Asp05Met06Pro07(nme-
Leu)08(D-Ala)09Arg10 
[Cha7]EP67 1297.7 
   Tyr01Ser02Phe03Lys04Asp05Met06Cha07(nme-
Leu)08(D-Ala)09Arg10 
[Leu8]EP67 1227.6 





   Tyr01Ser02Phe03Lys04Asp05Met06Cha07Leu08(D-
Ala)09Arg10 
 
Table 4.1. Relevant sequences and molecular masses of C5a, C5a desArg, 
EP54, EP67, and EP67 analogs. Cha = cyclohexylalanine; nme-Leu = N-methyl 
leucine. Molecular masses of C5a and C5a desArg vary due to differences in 
glycosylation levels. C5a was not used in the current study because it is quickly 














Table 4.2. RP-HPLC Characteristics of EP54, EP67, and EP67 analogs. Cha 
= cyclohexylalanine. Retention time and purity were determined from RP-HPLC 
chromatograms using the indicated column. aACE 5 C18-300 column (250 x 4.6 
































       
EP54 24.4 86.2 24.9 87.2 23.8 87.2 
EP67 27.4 96.9 27.4 96.1 22.3 94.4 
[Cha7]EP67  34.4 96.4 33.1 93.9 28.9 96.5 
[Leu8]EP67 26.1 99.1 25.1 99.0 20.7 99.7 
[Cha7Leu8]EP67  34.5 97.4 31.8 95.5 28.2 99.2 
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Table 4.3. Measured molecular masses of EP54, EP67, and EP67 analogs. 
Cha = cyclohexylalanine; nme-Leu = N-methyl leucine. Experimental masses 





















    
EP54 1209.6454 1209.6455 0.1 
EP67 1241.6352 1241.6350 0.2 
[Cha7] EP67  1297.6978 1297.6984 0.5 
[Leu8] EP67 1227.6196 1227.6196 0.0 
[Cha7Leu8] EP67 1283.6822 1283.6821 0.2 
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Peptide Asx Ser Ala Met Leu Tyr Phe Lys Arg Pro 
           




























































































Table 4.4. Amino acid compositions of EP54, EP67, and EP67 analogs. Cha 
= cyclohexylalanine; nme-Leu = N-methyl leucine. Samples were subjected to 
vapor-phase hydrolysis in constant boiling 6M hydrochloric acid for 24 hours prior 
















Table 4.5 Potencies and EMAX of IL-6 and TNF-α secretion from human monocytes, M0-
monocyte-derived macrophages, and monocyte-derived dendritic cells after treatment 
with human C5a desArg, EP54, EP67, or EP67 analogs for 24 h. Values were calculated from 
dose response curves for (A.) human monocytes (MC), (B.) M0-monocyte-derived macrophages 
(M0-MDM), and (C.) monocyte-derived dendritic cells (MDDC) (Figure 2). Cha = 
cyclohexylalanine. n = number of healthy, young human adult male blood donors. aEC50 = 
average molar peptide concentration that stimulated 50% maximum secretion of the indicated 
cytokine [±95%CI]. bEMAX = average maximum mass concentration of secreted cytokine 
[±95%CI]. cpD2 = - log (EC50) [±95% CI]. d∆C5a desArg = pD2 (C5a desArg) - pD2 (peptide). 
e%C5a desArg Potency = antilog (-∆C5a desArg) x 100.  
 






































































































7 [±0.1] 1.5 1.1 2.9 7.7 
B. M0-
MDM 
































































































1.64 1.42 2.28 3.78 
C. 
MDDC 




































































































Table 4.6 Potencies and EMAX of myeloperoxidase secretion from human 
neutrophils after treatment with human C5a desArg, EP54, EP67, or EP67 
analogs for 24 h. Values were calculated from dose response curves of human 
neutrophils (NP). Cha = cyclohexylalanine. n = number of healthy, young human 
adult male blood donors. aEC50 = average molar concentration that stimulated 50% 
maximum secretion of myeloperoxidase (MPO) [±95%CI]. bEMAX = average 
maximum mass concentration of secreted MPO [±95%CI]. cpD2 = - log (EC50) 
[±95% CI]. d∆C5a desArg = pD2 (C5a desArg) - pD2 (peptide). e%C5a desArg 






















NP  MPO MPO MPO MPO MPO 









































Table 4.7 Selectivities of human C5a desArg, EP54, EP67, and EP67 analogs 
for the activation of human monocytes, M0-monocyte-derived macrophages, 
and monocyte-derived dendritic cells vs. human neutrophils. Average 
selectivities [± propagated 95% CI] were calculated. Cha = cyclohexylalanine. n = 
number of healthy, young human adult male blood donors. aMC vs. NP Selectivity 
= [antilog (-∆C5a desArg MC) - (-∆C5a desArg NP)], bM0-MDM vs. NP selectivity 
= [antilog (-∆C5a desArg M0-MDM) - (-∆C5a desArg NP)], and c MDDC vs. NP 
selectivity = [antilog (-∆C5a desArg MDDC) - (-∆C5a desArg NP)] where ∆C5a 
desArg = pD2 (C5a desArg) - pD2 (peptide) and pD2 = - log (EC50[M]) in the 












aMC vs. NP 
Selectivity 
bM0-MDM vs. NP 
Selectivity 
cMDDC vs. NP 
Selectivity 
  IL-6 TNF-α IL-6 TNF-α IL-6 TNF-α 
C5a desArg 3 1 1 1 1 1 1 





































































The decapeptide EP67 is a novel host-derived immunostimulants based on 
the C-terminal of C5a that selectively activates phagocytes over neutrophils. In 
contrast to C5a65-74 from the C5a parent molecule, EP67 has topographical 
features that are well accommodated by C5aRs expressed on phagocytes- 
monocytes, macrophages, and dendritic cells, but not C5aRs neutrophils. Thus, 
EP67 induces host innate immune responses against normal and resistant 
infections via engagement of C5aR-bearing phagocytes with little/no inflammatory 
side-effects associated with the direct activation of neutrophils. 
The Pro residue at position 7 (Pro7) is critical for the potency and selectivity 
of EP67. It was placed in this position to force an extended conformation at the 
carbonyl carbon between the  and  bonds in the Met backbone to its N-
terminus, a feature that was found to be biologically important from SAR studies 
with the previous analog of EP67, EP54. The Pro residue, however, undergoes 
cis/trans isomerization that leads to conformers of EP67 in solution, making it 
unclear whether cis/trans isomerization is important to the biological properties of 
EP67 or if one conformer is more effective than the other. What is clear is that the 
conformational influence of Pro at this position is important for the activity and bio-
selectivity of EP67. Thus, the goals of this project were to (i.) develop a clinically 
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relevant, high-throughput assay for screening immunostimulant activity in primary 
human mononuclear phagocytes (monocytes, unpolarized (M0)-monocyte-derived 
macrophages, monocyte-derived dendritic cells) and neutrophils and (ii.) 
determine whether replacing Pro7 with cyclohexylalanine and/or nme-Leu8 with 
leucine adversely affects EP67 potency and efficacy in human mononuclear 
phagocytes and selective activation vs. human neutrophils.  
In this project, we established a more clinically relevant, high throughput 
assay to determine immunostimulants activity in human monocytes, unpolarized 
monocytes-derived macrophages, monocytes-derived dendritic cells, and human 
neutrophils. Using this assay, we found that replacing Pro7 with cyclohexylalanine 
and/or nme-Leu8 with native Leu selectively affects EP67 potency and efficacy in 
human mononuclear phagocytes without affecting selective activation over human 
neutrophils. Thus, replacing Pro7 and nme-Leu8 with amino acids expected to 
induce similar structure changes is a suitable approach for generating future 
analogs of EP67. 
5.2 FUTURE DIRCTIONS 
Using our assay, we will continue screening for more EP67 analogs, and 
we expect that at least one analog with a 5 to 10-fold higher C5aR potency and 
bio-selectivity than EP67. Once identified, these analogs will be assessed for their 
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effectiveness in inducing innate immune responses against resistant bacterial 
(MRSA) infections. Briefly, we will demonstrate the therapeutic efficacy of 
EP67/analog in inducing host-innate immune responses against local and 
systemic methicillin-resistant Staphylococcus aureus (MRSA) infections in the 
human-relevant porcine model. We will also evaluate both the prophylactic and 
therapeutic efficacy of EP67/analog against these MRSA infections and will 
characterize the molecular and cellular elements of innate immune outcomes 
responsible MRSA reduction/elimination. We will establish the duration of the 
EP67-mediated protective effects to MRSA infections in the skin, blood, and kidney 
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